LPF-NTs are commonly treated by surgical resection. In up to 30% of these resections, the<unk>  recurs at the surgical site apparently because the resections did not remove all of the<unk> . Recurrences of the<unk>  have been successfully treated by repeated resections. However, there one reported case and it is expected that there will be future case of LPF-NT that because of their<unk> s' location, size, or aggressiveness, require alternatives or adjuvants to surgical resection. The authors of many studies have suggested that one promising alternative and/or adjuvant to surgical treatment of LPF-NTs is to inhibit the action of the NTRK1 gene's product, TrkA. As indicated in the above section on gene abnormalities, about 80% (19 of 24 cases) of LPF-NTs contain NTRK1-containing fusion genes that produce abnormally high levels of overactive and uncontrolled tropomyosin receptor kinase A activity which may promote the development and/or progression of LPF-NTs. Two inhibitors of receptor tyrosine kinase activity, larotrectinib and entrectinib, have been shown to be effective in phase I (screening for safety) and phase II (assessing dosage requirements and efficacy) clinical trials in patients with various types of Trk fusion gene-positive<unk> s although not in LPF-NTs. In 2018, the Food and Drug Administration approved larotrectinib for adult and pediatric patients with solid<unk> s that: 1) have an NTRK-containing fusion gene that is not resistant to the drug; 2) are metastatic or surgically inaccessible; 3) have no satisfactory alternative treatment; or 4) have progressed after treatment. In 2020, a young adult presented with a spinal LPF-NT that, because of its size and location, was deemed surgically unresectable. The patient was treated in a clinical trial with entrectinib. The treatment reduced the<unk> 's size by 45% within 20 weeks at which time it was removed surgically and found to consist of 95% necrotic cells. While further clinical trials on many more individuals are needed, Tka-inhibitors may have a role as adjuvants to surgery or in various severe cases as the main treatment of LPF-NTs.
Lipofibromatosis-like neural tumor
Neural fibrolipoma
Eccrine angiomatous hamartoma
Embryonal tumour with multilayered rosettes
Folliculosebaceous cystic hamartoma
Intranodal palisaded myofibroblastoma
Perivascular epithelioid cell tumour
Aggressive angiomyxoma